AstraZeneca PLC (LON:AZN)
11,870
-162 (-1.35%)
Oct 2, 2026, 4:36 PM GMT
AstraZeneca Employees
AstraZeneca had 96,100 employees as of December 31, 2025. The number of employees increased by 1,800 or 1.91% compared to the previous year.
Employees
96,100
Change (1Y)
1,800
Growth (1Y)
1.91%
Revenue / Employee
481.29K GBP
Profits / Employee
81.93K GBP
Market Cap
184.11B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 96,100 | 1,800 | 1.91% |
| Dec 31, 2024 | 94,300 | 4,400 | 4.89% |
| Dec 31, 2023 | 89,900 | 6,400 | 7.66% |
| Dec 31, 2022 | 83,500 | 400 | 0.48% |
| Dec 31, 2021 | 83,100 | 7,000 | 9.20% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| GSK plc | 66,841 |
| Haleon | 24,535 |
| Spire Healthcare Group | 17,800 |
| Smith & Nephew | 17,000 |
| Convatec Group | 10,000 |
| Hikma Pharmaceuticals | 9,500 |
| CVS Group | 9,000 |
| Genus | 3,190 |
AstraZeneca News
- 2 days ago - AstraZeneca Stocks Moves Lower as Datroway Combination Enters Phase 3 - GuruFocus
- 2 days ago - Weekly Buzz: EW, ABBV, MIRM Score FDA Wins, AZN, NVO Strike Deals; LLY, KOD Report Data - Nasdaq
- 2 days ago - AstraZeneca Trillion-Pound Valuation: Can the Pipeline Deliver It? - ABC Money
- 2 days ago - Summit Therapeutics enters trial collaboration with AstraZeneca, Daiichi Sankyo - TheFly
- 2 days ago - Daiichi Sankyo, AstraZeneca, Summit Partner On Datroway- Ivonescimab Cancer Studies - Nasdaq
- 2 days ago - Daiichi Sankyo, AstraZenca, Summit Partner To Evaluate Datroway Plus Ivonescimab - Nasdaq
- 2 days ago - AstraZeneca, Daiichi Sankyo partner with Summit to test cancer drug combination - Reuters
- 2 days ago - Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor Types - Business Wire